<DOC>
	<DOCNO>NCT00298025</DOCNO>
	<brief_summary>To demonstrate comparative safety efficacy Cetrotide® 3 milligram ( mg ) Antagon™ inhibition premature luteinizing hormone ( LH ) surge woman undergo ovarian stimulation recombinant human follicle stimulate hormone/human menopausal gonadotropin ( r-hFSH/hMG ) prior assist reproductive technology ( ART ) utilize oral contraceptive pill ( OCP ) cycle programming .</brief_summary>
	<brief_title>A Study Compare Safety Efficacy Cetrotide® 3 Milligram ( mg ) Versus Antagon™ Women Undergoing Ovarian Stimulation</brief_title>
	<detailed_description />
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>Infertile woman wish conceive whose physician recommend undergo ART Aged 1839 year ( inclusive ) Regular menstrual cycle every 2535 day Body mass index ( BMI ) less 35 kilogram per square meter ( kg/m^2 ) Has transvaginal pelvic ultrasound scan within 6 week prior OCP administration , well Hysterosalpingography ( HSG ) hysterosonogram hysteroscopy within three year prior OCP administration show clinically significant pelvic and/or uterine abnormality , , Investigator 's opinion , could impair ovarian response , embryo implantation pregnancy continuation Normal cervical cytology , document Pap Smear , within six month prior OCP administration If subject prior stimulation cycle , least 60day washout period require last dose gonadotropin clomiphene citrate ; 60day washout require last dose Lupron® Lupron Depot® 1month ; 180day washout period require last dose treatment DepoProvera® Lupron Depot® 6month ; 60day washout require last dose oral contraceptive prior OCP administration study Screening laboratory result follicle stimulate hormone ( FSH ) within normal limit early follicular phase local laboratory Is willing able comply protocol duration study Has voluntarily provide write informed consent subject authorization Health insurance portability accountability act ( HIPAA ) , prior studyrelated procedure part normal medical care , understand subject could withdraw consent time without prejudice future medical care Clinically significant systemic disease Known infect Human Immunodeficiency Virus ( HIV ) Known infect Hepatitis C virus Known test positive Hepatitis B surface antigens Any medical condition , , judgment Investigator Sponsor , may interfere absorption , distribution , metabolism excretion study drug Known endometriosis Grade IIIIV ( American society reproductive medicine [ ASRM ] classification ) Uni bilateral hydrosalpinx Any contraindication pregnant and/or carry pregnancy term Any previous ART cycle indicate poor response gonadotropin stimulation ( define retrieval three oocytes less ) If , previous ART attempt , motile sperm sperm processing ejaculate , epididymal , testicular , fresh frozen/thawed spermatozoa Three previous consecutive ART cycle without clinical pregnancy An extrauterine pregnancy within last three month OCP treatment commences Abnormal , undiagnosed , gynecological bleeding Known allergy hypersensitivity human gonadotropin preparation studyrelated medication Known current substance abuse Previous participation study simultaneous participation another clinical trial Current smoker</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Infertility</keyword>
	<keyword>Cetrotide</keyword>
	<keyword>Antagon</keyword>
	<keyword>Recombinant human follicle stimulate hormone ( r-hFSH )</keyword>
	<keyword>Human Menopausal Gonadotropin ( hMG )</keyword>
	<keyword>Recombinant Human Choriogonadotropin ( r-hCG )</keyword>
</DOC>